How to Help Your Patients Save Money on Nemluvio: A Provider's Guide to Savings Programs

Nemluvio (nemolizumab-ilto) represents a significant advance in treatment for prurigo nodularis and atopic dermatitis. But its retail cost — approximately $4,356–$6,144 per 30 mg pen — can be a major barrier if you don't actively navigate the available savings programs on your patients' behalf. This guide gives you a complete overview of every financial assistance pathway available through Galderma Patient Services (GPS) for Nemluvio, so you can remove cost as a barrier to effective treatment.

Why Provider-Initiated Enrollment Matters

Patients rarely navigate specialty drug savings programs on their own. Unlike picking up a manufacturer coupon at a retail pharmacy, Nemluvio savings programs require proactive enrollment — typically initiated in your office at the time of prescribing. Without that enrollment, patients face the full specialty drug pricing, which is prohibitive for most.

Best practice: Discuss financial assistance programs at the prescribing visit. Have your office submit the complete GPS Enrollment Form — including the program elections — rather than leaving patients to figure this out independently after the appointment.

Program 1: Commercial Copay Assistance Program

The GPS for Nemluvio Commercial Copay Program is the most impactful savings tool for commercially insured patients and the one most likely to apply to your working-age patient population.

Benefit: Eligible patients may pay as little as $0 per dose, up to $15,000 in annual savings

Eligibility: Commercially insured patients only (NOT Medicare, Medicaid, TRICARE, or other government-funded insurance)

Enrollment: Check the Copay Assistance box on the GPS Enrollment Form; patient must sign the authorization section; submit to Galderma

Renewal: Patients still on therapy are automatically re-enrolled annually — no action needed at the start of each benefit year

Limits: Annual maximum savings of $15,000; out-of-pocket cost reductions for eligible patients may vary

Program 2: Quick Start Program (Free Starter Supply During PA Processing)

The Quick Start program is critical for patients with active, high-burden disease who cannot wait weeks for prior authorization approval. It provides initial Nemluvio doses at no cost while PA is being processed.

What's provided: The 60 mg loading dose (two pens) plus up to 2 additional monthly refills at no charge

Eligibility: Treatment-naïve, commercially insured patients with a pending prior authorization

How to activate: Check the Quick Start box on the GPS Enrollment Form AND include a separate Free Goods prescription (a separate Rx signed by the prescriber). This second prescription is required and frequently missed, leading to Quick Start delays.

Program 3: Bridge Program (Coverage Gap Support)

The Bridge Program helps patients maintain access to Nemluvio when they experience a gap in coverage — for example, if they lose their job, change insurance plans, or are waiting on re-authorization after a denied appeal.

Situations covered: Insurance change or loss, delayed re-authorization, exhausted Quick Start supply during pending payer determination

Enrollment: Patient or provider calls GPS at 1-855-636-5884 and explains the coverage gap; program eligibility is determined case-by-case

Program 4: Patient Assistance Program (Uninsured/Underinsured Patients)

For patients who have no insurance, have government insurance that doesn't cover Nemluvio, or face copays that create a financial hardship, the Patient Assistance Program (PAP) provides Nemluvio at no cost to eligible patients.

Eligibility: Income criteria apply; uninsured, underinsured, or patients for whom no other assistance program applies

How to apply: Complete the PAP section on the GPS Enrollment Form or call 1-855-636-5884. Your prescriber signature is required. Income documentation from the patient may be needed.

Program 5: Replacement Program (Damaged or Unusable Doses)

Nemluvio is temperature-sensitive. If a dose is damaged during shipping, dropped, or otherwise rendered unusable, the Replacement Program provides up to 2 replacement pens per year at no charge to eligible commercially insured patients. Patients should call GPS immediately if they suspect a cold-chain failure.

Medicare and Medicaid Patients: Special Considerations

Commercial copay assistance programs cannot be used by patients with Medicare or Medicaid. For these patients:

Medicare Part D: Nemluvio may be covered as a specialty tier drug. As of 2026, the Part D annual out-of-pocket cap is $2,100 — after that, the plan covers 100%. Encourage patients to enroll during Open Enrollment in a Part D plan that covers Nemluvio.

Patient Assistance Program: Medicare patients who don't have Part D coverage, have exhausted their annual cap, or cannot afford their cost-share may qualify for the PAP. Galderma's determination is case-by-case.

Quick Reference: Which Program for Which Patient?

Commercially insured, PA pending: Quick Start (free starter supply) + Copay Assistance Program

Commercially insured, PA approved: Copay Assistance Program (as little as $0/dose, max $15,000/year)

Coverage gap or insurance change: Bridge Program

Uninsured or insufficient coverage: Patient Assistance Program (income-based)

Damaged or unusable dose: Replacement Program (up to 2 pens/year, commercially insured)

How medfinder Supports Your Practice and Patients

When your patients encounter specialty pharmacy access obstacles — whether due to enrollment delays, PA appeals, or insurance transitions — medfinder helps them identify which pharmacies can fill their prescription without repeated frustrating phone calls. Direct patients and staff to medfinder.com/providers for this support. For the full access workflow, review our provider guide to helping patients find Nemluvio.